Alteogen Inc.
196170
Clasificación en acciones
#1836
ALTEOGEN Inc., a bio company, focuses on developing long-acting biobetters,... ALTEOGEN Inc., a bio company, focuses on developing long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars. The company develops ALT-P1, a long-acting human growth hormone that is in the Phase IIa clinical trial; and ALT-Q2, a long-acting active form of coagulation factor VII for the treatment of hemophilia based on its NexP technology. It is also involved in the development of ALT-P7, a targeted breast/gastric cancer drug that is in the Phase I clinical trial; ALT-Q5, an antibody-drug conjugate (ADC) for the treatment of ovarian cancer based on its NexMab ADC technology; and ALT-LS2, a SC (subcutaneous) formulation of trastuzuamb for the treatment of breast and gastric cancer. The company has a strategic alliance with Kissei Pharmaceutical for the development of ALT-L9, a biosimilar of Eylea (Aflibercept) which is currently under Phase 1 trial; Cristalia for the development of ALT-L2, a biosimilar of Herceptin (Trastuzumab), a monoclonal antibody for the treatment of breast cancer, which is in the Phase II clinical trial; and Biogen Inc. to develop subcutaneous (SC) formulations of biologics utilizing ALT-B4. ALTEOGEN Inc. was founded in 2008 and is headquartered in Daejeon, South Korea.
Precio por acción
$165.61
Capitalización bursátil
$11.53B
Cambio (1 día)
4.13%
Cambio (1 año)
-46.48%
País
KR
Comercio Alteogen Inc. (196170)
Categoría
Healthcare
Ingresos de Alteogen Inc. (196170)
Ingresos en Jun 2026 TTM: $175.65M
Según los últimos informes financieros de Alteogen Inc., los ingresos actuales de la empresa (TTM) son $175.65M. En 2023, la empresa obtuvo unos ingresos de $74.56M un aumento con respecto a los ingresos del año 2022, que fueron de $22.83M. Los ingresos representan la cantidad total que una empresa genera por la venta de bienes o servicios. A diferencia de las ganancias, no se restan los gastos.
Historial de ingresos de Alteogen Inc. desde 2012 hasta 2026
Ingresos al final de cada año
| Año | Ingresos | Cambiar |
|---|---|---|
| 2026 (TTM) | $175.65M | 151.07% |
| 2024 | $69.96M | -6.17% |
| 2023 | $74.56M | 226.63% |
| 2022 | $22.83M | -29.96% |
| 2021 | $32.59M | -16.60% |
| 2020 | $39.08M | 54.39% |
| 2019 | $25.31M | 105.68% |
| 2018 | $12.31M | 8.35% |
| 2017 | $11.36M | 100.10% |
| 2016 | $5.68M | 41.12% |
| 2015 | $4.02M | -37.51% |
| 2014 | $6.44M | 22.58% |
| 2013 | $5.25M | 41.14% |
| 2012 | $3.72M | 0.00% |
Ingresos de empresas similares o competidoras
| Empresa | Ingresos | Diferencia de ingresos | País |
|---|---|---|---|
| $12.62B | 7,087.26% |
US
|
|
| $2.23B | 1,168.44% |
US
|
|
| $15.74B | 8,863.55% |
AU
|
|
| $6.02B | 3,328.04% |
NL
|
|
| - | - |
CH
|
